The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|8|2|247-256

ISSN： 1389-4501

Source： Current Drug Targets, Vol.8, Iss.2, 2007-02, pp. : 247-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders

By  

Current Drug Targets, Vol. 8, Iss. 2, 2007-02 ,pp. : 205-216

Bentham Science Publishers

Access to resources Recommend Favorite

Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease

By Antoniu Sabina A  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 329-332

Informa Healthcare

Access to resources Recommend Favorite

The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 11, Iss. 2, 2012-04 ,pp. : 159-168

Bentham Science Publishers

Access to resources Recommend Favorite

Myeloproliferative disorders

By Murray Jim  

Clinical Medicine, Vol. 5, Iss. 4, 2005-07 ,pp. : 328-332

Royal College Of Physicians

Access to resources Recommend Favorite

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

By  

Current Drug Targets, Vol. 12, Iss. 3, 2011-01 ,pp. : 392-419

Bentham Science Publishers

Access to resources Recommend Favorite